Enantiospecific effects of cytochrome p450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 62-75

  Kirchheiner, Julia ^a,b   Meineke, Ingolf ^a   Freytag, Georg ^a   Meisel, Christian ^a   Roots, Ivar ^a   Brockmöller, Jürgen ^a  

^a University of Göttingen ^*

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; ENZYME VARIANT; IBUPROFEN; PROSTAGLANDIN E2; THROMBOXANE B2;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME IMMUNOASSAY; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; ALGORITHMS; ALLELES; AMINO ACID SUBSTITUTION; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DINOPROSTONE; GENOTYPE; HALF-LIFE; HUMANS; IBUPROFEN; MALE; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; THROMBOXANE B2;

EID: 0036336114     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.125726     Document Type: Article

References (51)

1. Clinical pharmacokinetics of ibuprofen: The first 30 years
2. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis
3. Isomeric inversion of ibuprofen (R)-enantiomer in humans
4. Stereoselective disposition of ibuprofen enantiomers in man
5. Stereoselective disposition of ibuprofen enantiomers in synovial fluid
6. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers
7. Molecular cloning and expression of a 2-arylpropionylcoenzyme A epimerase: A key enzyme in the inversion metabolism of ibuprofen
8. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs
9. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
10. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
11. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
12. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
13. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
14. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
15. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism
16. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
17. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
18. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes
19. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor
20. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen
21. Role of CYP2C9 polymorphism in losartan oxidation
22. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
23. Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: Relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen
24. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs
25. The coxibs, selective inhibitors of cyclooxygenase-2
26. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
27. High-performance liquid chromatographic determination of ibuprofen, its metabolites and enantiomers in biological fluids
28. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
29. 2: A simple method of assessing pharmacologic effects on platelet function
30. Radioimmunoassay measurement of stable metabolites of platelet arachidonic acid: A convenient method for the in vitro and ex vivo evaluation of cyclo-oxygenase inhibitors
31. A novel extravascular input function for the assessment of drug absorption in bioavailability studies
32. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes
33. Studies of flurbiprofen 4′-hydroxylation: Additional evidence suggesting the sole involvement of cytochrome P450 2C9
34. Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen
35. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation
36. 14C]Naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10
37. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver
38. Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model
39. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam
40. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4
41. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics
42. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
43. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity
44. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
45. Is diclofenac a valuable CYP2C9 probe in humans?
46. CYP2C9 genotype and diclofenac hydroxylation in a Spanish population
47. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
48. Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate
49. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin
50. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme